Will the FDA release a draft policy authorizing pharmacy compounding of non-approved peptides by 20 November 2026?
Posted 2026-10-29 — 22 days before the deadline, stated before the outcome.
The U.S. Food and Drug Administration (FDA) regulates the safety and efficacy of drugs, including those prepared by compounding pharmacies. This question concerns whether the agency will issue formal guidance permitting the preparation of peptides that have not received FDA approval.
The claim
By 2026-11-20, the FDA publicly releases a formal draft policy or guidance authorizing pharmacies to compound non-FDA-approved peptides.
Reasoning trace
- HHS Secretary RFK Jr. pushes pharmacies to compound non-FDA-approved peptides
- Draft policy circulates publicly and is covered by the press
- FDA publicly releases a formal draft policy or guidance authorizing the compounding
Evidence so far
7 confirming · 0 denying signals · 6 verified · 2 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 8 times since mint (last on 2026-10-31) — 49% at mint → 75% today.
What to watch
- milestone The FDA posts a public notice of availability for a new draft guidance document in the Federal Register
- precondition The HHS Secretary issues a public directive or statement mandating the development of this specific compounding policy
- milestone The FDA publishes the draft peptide compounding policy on its official website or in the Federal Register
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.